US HHS secretary tells Senate Finance Committee he believes pharmacy benefit managers will effectively keep drug costs down in Medicare Part D, even without rebates.
The HHS proposal to eliminate prescription drug rebates in Medicare Part D will not lead to increased premiums and government spending despite some projections to the contrary, US HHS Secretary Alex Azar assured the Senate Finance Committee at a March 14 hearing.
The hearing focused on the President’s budget proposal for 2020. At the session, Azar fielded questions on a wide range...
Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.
Japan's NHI program continues to give and take as 11 new drugs are granted reimbursement, while the prices of others - including three ophthalmic therapies - are cut by up to 20% under a Market Expansion Repricing scheme.
MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.
